Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Primate cell – per se
Reexamination Certificate
2001-08-30
2003-11-25
Lankford, Jr., Leon B. (Department: 1651)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Primate cell, per se
C424S093700, C435S325000, C435S395000, C435S400000, C604S004010, C604S005020, C604S006040, C623S023650
Reexamination Certificate
active
06653131
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a method for treating systemic inflammatory response syndrome (SIRS) by contacting the bodily fluid of a patient with renal tubule cells outside of the kidney.
2. Background of the Invention
The mortality from sepsis complicated by renal failure remains extremely high despite the application of modem renal replacement therapy. The systemic inflammatory response syndrome, or SIRS, is a catastrophic sequela of a variety of clinical insults, including infection, pancreatitis, and cardiopulmonary bypass, and claims over a quarter million lives in the US each year. [Refs. 1, 2, 3, 4, 5, 6].
The exceptionally high mortality associated with the syndrome is due in part to the development of the highly lethal multiple system organ failure syndrome, or MSOF, in a subset of patients with SIRS. The sequential failure of organ systems apparently unrelated to the site of the initial insult has been correlated with altered plasma cytokine levels observed in sepsis. [Refs. 7, 8, 9, 10, 11, 12].
The mortality is especially high in patients with MSOF and acute renal failure (ARF). The excess mortality seen in patients with sepsis and ARF is not ameliorated by conventional renal replacement therapy, which treats volume overload, uremia, acidosis, and electrolyte derangements.[Refs. 13, 4].
Accordingly, there remains an ongoing need for new methods for treating patients with SIRS.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide methods for treating patients with SIRS.
The present invention is based, in part, on the discovery that a body fluid of a patient with SIRS can be contacted with renal tubule cells outside of the kidney. As a result of this contact, the tubule cells introduce mediators into the body fluid. After contact with the tubule cells, at least a portion of the body fluid is recirculated to the patient, where the mediators induce a response in the patient which leads to amelioration of the SIRS state. As a result of this contact, the tubule cells introduce mediators into and/or reabsorb mediators from the body fluid.
Accordingly, the present invention provides a method of treating a patient with SIRS, comprising:
contacting, outside of the kidney, at least a portion of a body fluid of the patient with renal tubule cells.
The present invention also provides a method of treating a patient with SIRS, comprising:
removing a portion of body fluid from the patient,
contacting the removed body fluid with renal tubule cells, and
returning at least a portion of the body fluid which has been contacted with the renal tubule cells to the patient.
REFERENCES:
patent: 3734851 (1973-05-01), Matsumura
patent: 4242460 (1980-12-01), Chick et al.
patent: 4354933 (1982-10-01), Lester
patent: 5360790 (1994-11-01), Humes
patent: 5429938 (1995-07-01), Humes
patent: 5516680 (1996-05-01), Naughton et al.
patent: 5549674 (1996-08-01), Humes et al.
patent: 5686289 (1997-11-01), Humes et al.
patent: 6060270 (2000-05-01), Humes
patent: 6150164 (2000-11-01), Humes
patent: 1 479 002 (1974-06-01), None
patent: WO 89/01967 (1989-03-01), None
patent: WO 91/00119 (1991-01-01), None
patent: WO 92/07615 (1992-05-01), None
patent: WO 93/17696 (1993-09-01), None
H. David Humes et al.,Replacement of Renal Function in Uremic Animals with a Tissue-Engineered Kidney, Nature Biotechnology, vol. 17, pp. 451-455, May 1999.
Roger C. Bone,Systemic Inflammatory Responses Syndrome: A Unifying Concept of Systemic Inflammation, Sepsis and Multiorgan Failure, 1997, pp. 3-10.
H. David Humes et al.,Tissue Engineering of a Bioartificial Renal Tubule Assist Device: In Vitro Transport and Metabolic Characteristics, Kidney International, vol. 55 (1999), pp. 2502-2514.
H. David Humes,Bioartificial Kidney for Full Renal Replacement Therapy, Seminars in Nephrology, vol. 20, No. 1, Jan. 2000, pp. 71-82.
John M. Walker et al,The Language of Biotechnology, 1988, p. 126.
R. Ian Freshney,Culture of Animal Cells, A Manual of Basic Technique, Second Edition, 1987, pp. 1-13, and pp. 197-206.
Sherrill M. MacKay et al.,Tissue Engineering of a Bioartificial Renal Tubule, ASAIO Journal, vol. 44, No. 3, May-Jun. 1998, pp. 179-183.
Sally Pobojewski,U Researchers Unveil Component of Bio-Artificial Kidney, The University Record, May 24, 1999.
Charles Natansonet et al.,Role of Endotodemia in Cardiovascular Dysfunction and Mortality, The Journal of Clinical Investigation, Inc., vol. 83, Jan. 1989, pp. 243-251.
Bradley D. Freeman et al.,Continuous Ateriovenous Hemofiltration Does Not Improve Survival in a Canine Model of Septic Shock, Journal of the American College of Surgeons, Mar. 1995, vol. 180, pp. 286-291.
J. A. Kellum,Immunomodulation in Sepsis: The Role of Hemofiltration, Minerva Anestesiologica, vol. 65, No. 6, pp. 410-418.
Gordon R. Bernard, M.D. et al.,Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis, The New England Journal of Medicine, vol. 344, No. 10, Mar. 8, 2001, pp. 699-709.
Diep D. Tranet et al.,Age, Chronic Disease, Sepsis, Organ System Failure, and Mortality in a Medical Intensive Care Unit, Critical Care Medicine, vol. 18, No. 5, pp. 474-479, May 1990.
S. C. Donnellyet et al.,Mediators, Mechanisms and Mortality in Major Trauma, Resuscitation, vol. 28, pp. 87-92, 1994.
Roger C. Bone, M.D. et al.,A Controlled Clinical Trial of High-Dose Methylprednisolone in the Treatment of Severe Sepsis and Septic Shock, The New England Journal of Medicine, vol. 317, No. 11, pp. 653-658.
K. D. Horn,Evolving Strategies in the Treatment of Sepsis and Systemic Inflammatory Response Syndrome(SIRS),Q. J. Med, 1998, vol. 91, pp. 265-277.
Michael R. Pinsky,Serum Cytokine Levels in Human Septic Shock, Chest, vol. 103, No. 2, Feb. 1993, pp. 565-575.
Claire Marty et al.,Circulating Interleukin-8 Concentrations in Patients with Multiple Organ Failure of Septic and Nonseptic Origin, Critical Care Medicine, vol. 22, No. 4, pp. 673-679, Apr. 1994.
Pierre Damas, M.D., Ph.D. et al.,Tumor Necrosis Factor and Interleukin-1 Serum Levels During Severe Sepsis in Humans, Critical Care Medicine, vol. 17, No. 10, pp. 975-978, Oct. 1989.
Charles A. Dinarello,The Proinflammatory.Cyotkines Interleukin-1 and Tumor Necrosis Factor and Treatment of the Septic Shock Syndrome, The Journal of Infectious Diseases, 1991: 163, pp. 1177-1184.
Thierry Calandra et al.,Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-1, Interferon-&agr;, and Interferon-y in the Serum of Patients with Septic Shock, The Journal of Infectious Diseases, 1990: 161, pp. 982-987.
J. X. Jiang et al.,Plasma Cytokines and Endotoxin Levels in Patients with Severe Injury and Their Relationship With Organ Damage, Injury, vol. 28, No. 8, pp. 509-513, 1997.
Dorothy Breen et al.,Acute Renal Failure as a Part of Multiple Organ Failure: The Slippery Slope of Critical Illness, Kidney International, vol. 53, Suppl. 66 (1998), pp. S-25-S33.
Mark J. Sarnak et al.,Mortality Caused by Sepsis in Patients with End-Stage Renal Disease Compared with the General Population, Kidney International, vol. 58 (2000), pp. 1758-1764.
Matthias Girndt et al.,Production in Interleukin-6, Tumor Necrosis Factor &agr; and Interleukin-10 in vitro Correlates with the Clinical Immune Defect in Chronic Hemodialysis Patients, Kidney International, vol. 47 (1995), pp. 559-565.
Matthias Girndt et al.,Impaired Cellular Immune Function in Patients with End-Stage Renal Failure, Nephrol Dial Transplant, (1999) 14: 2807-2810.
Melissa K. Thomas, M.D., Ph.D. et al.,Hyptovitaminosis D in Medical Inpatients, The New England Journal of Medicine, vol. 338, No. 12, Mar. 19, 1998, pp. 777-783.
Roger C. Bone, M.D.,Why Sepsis Trials Fail, JAMA, Aug. 21, 1996, vol. 276, No. 7, pp. 565-566.
Roger C. Bone, M.D.,Toward a Theory Regarding the Pathogenesis of the Systemic Inflammatory Response Syndrome: What we Do and Do Not Know about Cytokine Regulation, Crit Care Med, 1996, vol. 24, No. 1, pp. 163-172.
C. Erik Hack et al.,Interleukin-8 in Sepsis: Relation to Shock and Inflammatory Mediat
Lankford , Jr. Leon B.
The Regents of the University of Michigan
LandOfFree
Method of treating systemic inflammatory response syndrome does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating systemic inflammatory response syndrome, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating systemic inflammatory response syndrome will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3168401